IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors
Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations
Tracking News - More Details of Marketing Progress for IceSense3™ in Mainland China
IceCure is setting new standards in minimally-invasive tumor therapy for women’s health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, our core technology is based on cryoablation, using liquid nitrogen to create ultra-low freezing temperatures to destroy tumors safely, quickly, and painlessly in a minimally-invasive procedure.
Our ProSense™ cryoablation system, enables rapid minimally-invasive, safe, and effective treatment of breast lesions in-office or ambulatory hospital settings. The system provides physicians with full control over the procedure, ensuring that the treated zone is destroyed while leaving surrounding tissue undamaged. The ProSense™ system is a proven solution for the treatment of benign and malignant breast tumors, as well as renal, lung, and bone cancer. The FDA cleared and CE marked ProSense system is available in the US, Europe, and across Asia in Singapore, Thailand, Japan, and Taiwan.
IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
IceCure Medical, LTD
CFO / COO
7 Ha'Eshel St
PO Box 3163
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598